Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724612 | 0.88 | HCAR3 (0.33) | GBA1USP2ALOX15 | |
| SCHEMBL4723020 | 0.85 | CRHR1 (0.33) | USP2ALOX15SMN1; SMN2 | |
| SCHEMBL4724056 | 0.83 | HCAR3 (0.39) | — | |
| SCHEMBL4724209 | 0.80 | — | — | |
| SCHEMBL4763927 | 0.79 | HTT (0.35) | GBA1SMN1; SMN2 | |
| SCHEMBL11242253 | 0.78 | DNM1 (0.31) | SMN1; SMN2 | |
| SCHEMBL4722178 | 0.77 | HCAR3 (0.35) | SMN1; SMN2 | |
| SCHEMBL4721493 | 0.72 | HCAR3 (0.37) | — | |
| SCHEMBL622400 | 0.72 | — | — | |
| SCHEMBL232139 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406420-B | Substituted triazoles and methods related thereto | 纽罗克里生物科学有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-5484903-A | Process for the production of polysaccharide carbonates | WOLFF WALSRODE AKTIENGESELLSCHAFT (DE) | 1996-01-16 | — | — | US | disclosed |
| EP-0367002-B1 | Carbonic-acid esters of polysaccharides and process for their preparation | WOLFF WALSRODE AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0532995-A2 | Process for preparing polysaccharide carbonates | Wolff Walsrode Aktiengesellschaft (DE) | 1993-03-24 | — | — | EP | disclosed |
| EP-0512319-A2 | Process for preparing carbonic acid derivatives of polysaccharides | Wolff Walsrode Aktiengesellschaft (DE) | 1992-11-11 | — | — | EP | disclosed |
| US-5068321-A | CARBONIC ACID ESTERS OF POLYSACCHARIDES AND A PROCESS FOR THEIR PRODUCTION | WOLFF WALSRODE AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0367002-A1 | Carbonic-acid esters of polysaccharides and process for their preparation | Wolff Walsrode Aktiengesellschaft (DE) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | GBA1 3649/4885USP2 4275/4885ALOX15 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.